Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:DASH 1 October 2025 - 10 December 2025

DoorDash (DASH) Stock After the Bell on December 9, 2025: Insider Fireworks, Lofty Valuation and What to Watch Before the December 10 Open

DoorDash (DASH) Stock After the Bell on December 9, 2025: Insider Fireworks, Lofty Valuation and What to Watch Before the December 10 Open

DoorDash shares closed at $229.99 on December 9, up 2.02%, after news of a $100 million insider purchase by director Alfred Lin. The move came amid ongoing insider selling and a new company report. After-hours trading saw the stock drift slightly lower, with no major volatility. DASH remains about 30% higher year-over-year, well above its 52-week low.
10 December 2025
···
DoorDash (DASH) Stock Today: Price, Fresh News, Analyst Forecasts and Outlook as of December 8, 2025

DoorDash (DASH) Stock Today: Price, Fresh News, Analyst Forecasts and Outlook as of December 8, 2025

DoorDash shares traded near $225 Monday, valuing the company at just under $97 billion, about 21% below October highs but up over 30% year to date. The company announced a national delivery partnership with Pacsun and faces a new class action lawsuit over an alleged data breach. Heavy institutional buying continues amid debate over DoorDash’s valuation and 2026 investment plans.
8 December 2025
·
DoorDash (DASH) Stock Rallies as $100 Million Insider Bet and Analyst Upgrades Clash With Amazon’s 30‑Minute Delivery Push

DoorDash (DASH) Stock Rallies as $100 Million Insider Bet and Analyst Upgrades Clash With Amazon’s 30‑Minute Delivery Push

DoorDash shares traded around $222 Wednesday afternoon, up sharply from November lows but still 20% below October’s peak. The stock briefly jumped over 3% intraday after renewed analyst optimism and heavy insider buying, following a volatile month of earnings-driven swings, regulatory headlines, and Amazon’s new ultra-fast delivery test. Market value hovered near $94 billion.
3 December 2025
··
Deliveroo Becomes First UK Delivery App to Offer Nectar Points on Sainsbury’s Orders

Deliveroo Becomes First UK Delivery App to Offer Nectar Points on Sainsbury’s Orders

From 27 November 2025, Sainsbury’s customers can earn Nectar points on grocery orders placed through Deliveroo, marking the first integration of Nectar with a UK delivery platform. The partnership covers over 1,000 Sainsbury’s locations. Customers receive one Nectar point per £1 spent on eligible items. The move follows Deliveroo’s £3.9 billion acquisition by DoorDash.
29 November 2025
···
DoorDash (DASH) Stock Today, November 26, 2025: Price Action, Australian Gig‑Worker Deal, Data Breach Fallout and Holiday Push

DoorDash (DASH) Stock Today, November 26, 2025: Price Action, Australian Gig‑Worker Deal, Data Breach Fallout and Holiday Push

DoorDash shares closed at $195.49 on Tuesday, up 3.94%, but remain 31% below their October peak after a sharp selloff following Q3 earnings and increased 2026 investment plans. The company faces a recent data breach, an $18 million legal settlement, and regulatory scrutiny, even as it reports strong order and revenue growth and signs a landmark gig-worker pay deal in Australia.
26 November 2025
··
DoorDash (DASH) plunges as 2026 spending plan eclipses Q3 beat — What to know today (Nov 6, 2025)

DoorDash (DASH) plunges as 2026 spending plan eclipses Q3 beat — What to know today (Nov 6, 2025)

DoorDash shares fell about 9% premarket after the company said it will boost 2026 spending by several hundred million dollars to accelerate a new global tech platform, overshadowing strong Q3 results. Revenue rose 27% to $3.45 billion and total orders climbed 21%, but EPS of $0.55 missed estimates. The Deliveroo acquisition closed Oct. 2. DoorDash’s $5 billion buyback remains unused.
6 November 2025
··
DoorDash’s DOT: The Little Robot That Could – Is Suburban Delivery About to Be Revolutionized?

DoorDash (DASH) Stock Today — Nov. 5, 2025: Q3 beat on revenue and GOV, but 2026 spend plans trigger sharp after‑hours selloff

DoorDash reported Q3 2025 revenue of $3.45 billion, up 27% year-over-year, with Marketplace GOV at $25 billion and GAAP net income of $244 million. Shares fell about 16% after hours as investors reacted to a profit miss and plans for several hundred million dollars in additional spending in 2026. The company guided Q4 GMV to $28.9–$29.5 billion.
5 November 2025
··
DoorDash’s DOT: The Little Robot That Could – Is Suburban Delivery About to Be Revolutionized?

DASH Stock Today (Nov. 5, 2025): DoorDash Slides After Q3 EPS Miss Despite Strong Sales; Bold 2026 Spend and Big Q4 GMV Guidance

DoorDash shares dropped as much as 16% after hours Wednesday after third-quarter earnings missed estimates and management signaled “several hundred million” dollars in extra investment for 2026. Revenue reached $3.45 billion, beating forecasts, but EPS came in at $0.55 versus $0.68 expected. The company raised holiday-quarter guidance and reported strong order growth.
5 November 2025
··
DoorDash’s DOT: The Little Robot That Could – Is Suburban Delivery About to Be Revolutionized?

DoorDash’s DOT: The Little Robot That Could – Is Suburban Delivery About to Be Revolutionized?

DoorDash has launched Dot, a 350-pound electric delivery robot now operating in Tempe and Mesa, Arizona. Dot uses cameras, radar, and LiDAR to navigate roads, bike lanes, and sidewalks, carrying up to 30 pounds at speeds up to 20 mph. DoorDash’s AI system matches orders to Dot, drones, or humans based on logistics. Experts have raised concerns about safety and the robot’s ability to handle real-world obstacles.
1 October 2025
···
1 2

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Go toTop